HEMATOPOIETIC PROGENITOR CELLS

乳腺癌是最常见的女性癌症。它的发病率是 在较年轻的女性中迅速增加，因为早期发现的情况很少。 肿瘤往往更具侵袭性，多产年限的损失 太棒了。大剂量自体造血祖细胞化疗 细胞支持(AHPCS)已被证明对预后不良有效 乳腺癌患者。本报告的重点是对AHPCS的评价。 使用CD34造血祖细胞，然后将其 进一步操纵(S)。该项目的目标是： L。最大限度地减少自体移植乳腺癌的数量。 2.为乳腺癌患者提供快速持久的骨髓重建 接受HDC治疗的患者。 3.减少大量注入未经净化的AHPCS的毒性 使用纯化的祖细胞。 4.发展造血祖细胞的体外扩增作为一种新的 技术，并展示了它的临床应用。

Breast cancer is the most common female cancer. Its incidence is increasing rapidly in younger women, where early detection is infrequent, tumors tend to be more aggressive, and loss of productive years is greatest. High-dose chemotherapy with autologous hematopoietic progenitor cell support (AHPCS) has demonstrated effectiveness for poor-prognosis breast cancer patients. The focus of this ROl is the evaluation of AHPCS using CD34+ hematopoietic progenitor cells, which are then subjected to further manipulation(s). The goals of this project are to: l. Maximally decrease the amount of breast cancer in the autograft. 2. To produce rapid and durable marrow reconstitution in breast cancer patients receiving HDC. 3. To reduce the toxicity of infusing large volumes of unpurified AHPCS by using purified progenitor cells. 4. To develop ex vivo expansion of hematopoietic progenitors as a novel technology, and demonstrate its clinical utility.